Cargando…

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study

SIMPLE SUMMARY: Light-chain amyloidosis is a rare disease, and treatment for relapsed light-chain amyloidosis patients is an unmet need. Venetoclax is an oral medication that has proven great efficacy in many hematological cancers, including multiple myeloma. Venetoclax is considered a promising age...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lebel, Eyal, Kastritis, Efstathios, Palladini, Giovanni, Milani, Paolo, Theodorakakou, Foteini, Aumann, Shlomzion, Lavi, Noa, Shargian, Liat, Magen, Hila, Cohen, Yael, Gatt, Moshe E., Vaxman, Iuliana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046384/ https://www.ncbi.nlm.nih.gov/pubmed/36980596 http://dx.doi.org/10.3390/cancers15061710

Ejemplares similares

P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY
por: Lebel, Eyal, et al.
Publicado: (2023)

P1274: IMPACT OF AUTOLOGOUS TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL TRIPLETS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Amitai, Irina, et al.
Publicado: (2023)

Biomarkers in AL Amyloidosis
por: Fotiou, Despina, et al.
Publicado: (2021)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021)

PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS
por: Kastritis, Efstathios, et al.
Publicado: (2023)

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
por: Aumann, Shlomzion, et al.
Publicado: (2022)

Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study
por: Morgenstern, Yael, et al.
Publicado: (2021)

Monoclonal antibody-based therapies for Waldenström's macroglobulinemia
por: Fotiou, Despina, et al.
Publicado: (2022)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, Efstathios, et al.
Publicado: (2023)

Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
por: Nachmias, Boaz, et al.
Publicado: (2023)

Cardiopulmonary Exercise Physiology in AL Amyloidosis Patients with Cardiac Involvement and Its Association with Cardiac Imaging Parameters
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis
por: Lama, Niki, et al.
Publicado: (2022)

Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Do older patients truly benefit from advances in myeloma care?
por: Gatt, Moshe E., et al.
Publicado: (2022)

Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2021)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma
por: Lebel, Eyal, et al.
Publicado: (2022)

The lung in amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
por: Nachmias, Boaz, et al.
Publicado: (2022)

Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, E., et al.
Publicado: (2022)

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, E., et al.
Publicado: (2022)

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival
por: Gross Even-Zohar, Noa, et al.
Publicado: (2022)

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
por: Fotiou, Despina, et al.
Publicado: (2020)

Diagnostic Challenges and Solutions in Systemic Amyloidosis
por: Goldis, Rivka, et al.
Publicado: (2023)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
por: Shragai, Tamir, et al.
Publicado: (2022)

Chimeric antigen receptor T‐cell therapy is superior to standard of care as second‐line therapy for large B‐cell lymphoma: A systematic review and meta‐analysis
por: Shargian, Liat, et al.
Publicado: (2022)

Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review
por: Georgiopoulos, Georgios, et al.
Publicado: (2023)

PB2150: CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGES IIIA/IIIB AL AMYLOIDOSIS
por: Wechalekar, Ashutosh, et al.
Publicado: (2023)

B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORK
por: Roussel, M., et al.
Publicado: (2023)

A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options
por: Moutafi, Myrto, et al.
Publicado: (2019)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
por: Palladini, Giovanni, et al.
Publicado: (2022)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients
por: Sabbah, Rozan, et al.
Publicado: (2023)

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
por: Palladini, Giovanni, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1hpdqer7is0l5bhthqj2dtqe2q